TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01769573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
Study: NCT03250065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of prototype sensor to a standard endotracheal tube
Description: During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
Study: NCT03256708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolardii
Description: Prolardii: 2 capsules per day for 12 to 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients
Study: NCT03160365

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACQUISITION OF IMAGES
Description: In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
Study: NCT03904251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT03943043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D.
Study: NCT03404037

Intervention type: DIAGNOSTIC_TEST
Intervention: serum endostatin level
Description: An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA

Intervention type: DIAGNOSTIC_TEST
Intervention: serum endostatin level
Description: An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA
Study: NCT02680704

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP titrated mechanical ventilation
Description: Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
Study: NCT01683435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBA binding assay
Description: HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
Study: NCT03762265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT04231825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
Study: NCT02279654

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
Study: NCT02356588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Tablet 30 mcg
Study: NCT02216331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.
Study: NCT02914496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
Study: NCT02523079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Self-help Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Guidance
Study: NCT02356588

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Study: NCT02216331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Study: NCT04231617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP infusion
Description: CGRP infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP infusion
Description: CGRP infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00253435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC \>=1500/uL for three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell infusion
Description: Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10\^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10\^8 mononuclear cells/kg must be available.
Study: NCT01592227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: Marketed paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental paracetamol formulation
Study: NCT00253435

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
Study: NCT03865524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty implanted with GPS navigation system
Description: Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty implanted with standard guides.
Description: Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
Study: NCT03851731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexol
Description: Intranasal spray
Study: NCT03983746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: core stability exercises and treadmill training exercises
Description: Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
Study: NCT00253435

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC \> 1000/uL, platelets \> 30,000 / uL, and is \> 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
Study: NCT00490750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dor fundoplication
Description: Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupet fundoplication
Description: Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
Study: NCT01496677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg
Description: Single oral tablet of TR-701 FA to elderly subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg
Description: Single oral tablet of TR-701 FA to younger group (18-45 years old)
Study: NCT03711942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra orifice barrier
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra orifice barrier
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
Study: NCT04508257

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral feeding of Investigational Formula (Stage 1&2)
Description: Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral feeding of Control formula (Stage 1&2)
Description: Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breast feeding
Description: Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
Study: NCT03711942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Base
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
Study: NCT03648320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Daily doses of peanut flour (with 2-weekly incremental interval)
Study: NCT04744064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate
Description: Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate
Description: Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
Study: NCT04348344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training.
Study: NCT01973842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 mg triptorelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mg triptorelin
Study: NCT02453932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianzhi granule and placebo identified to donepezil
Description: 1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
Study: NCT01973842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4 mg triptorelin
Study: NCT02112422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
Study: NCT01284569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
Study: NCT04175652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.